Advanced search
Publication Cover
HIV Clinical Trials Volume 19, 2018 - Issue 6
Submit an article Journal homepage
877
Views
12
CrossRef citations to date
0
Altmetric
Brief Report

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects

Amedeo F. Capetti1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4633-1035
ORCID Icon,
Giuseppe V. De SocioInfectious Diseases Clinic, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy; ORCID Iconhttp://orcid.org/0000-0001-8774-4843
ORCID Icon,
Maria V. Cossu1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy;
,
Gaetana SterrantinoDivision of Infectious Diseases, “Careggi” Hospital, Firenze, Italy;
,
Giovanni CenderelloDivision of Infectious Diseases, Ospedali Galliera, Genova, Italy;
,
Annamaria CattelanInfectious and Tropical Diseases, Azienda Ospedaliera-Universitaria di Padova, Padova, Italy;
,
Gian M. Baldin2nd Division of Infectious Diseases, Università Cattolica del Sacro Cuore, Roma, Italy; ORCID Iconhttp://orcid.org/0000-0003-4623-9976
ORCID Icon,
Alessandro SoriaClinic of Infectious Diseases, San Gerardo Hospital, ASST Monza, University of Milano-Bicocca, Milan, Italy;
,
Niccolò RiccardiInfectious Diseases Clinic, “San Martino” Hospital, Genova, Italy;
,
Fosca P. Niero1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy;
,
Benedetto M. CelesiaInfectious Diseases Unit, University of Catania, ARNAS (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione) Garibaldi, Catania, Italy;
,
Giorgio Barbarini2nd Division of Infectious Diseases, “Policlinico San Matteo” Hospital, Pavia, Italy;
,
Stefano RusconiInfectious Diseases Unit, DIBIC Luigi Sacco, University of Milano, Milan, Italy;
&
Giuliano Rizzardini1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy; ;School of Clinical Medicine, Faculty of Health Sciences, Whitwaterstrand University, Johannesburg, South Africa
 show all
Pages 242-248 | Received 06 Aug 2018, Accepted 12 Nov 2018, Published online: 20 Mar 2019

References

  • Gubavu C, Prazuck T, Niang M, et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother. 2016;71(4):1046–1050.
  • Capetti AF, Sterrantino G, Cossu MV, et al. Switch to Dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One 2016;11(10):e0164753.
  • Gantner P, Cuzin L, Allavena C, et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017;18(9):704–708.
  • Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M. 2017. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 1060028017728294.
  • Palacios R, Mayorga M, González-Domenech CM, et al. Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care. 2018;17:2325958218760847.
  • Casado JL, Monsalvo M, Rojo AM, Fontecha M, Rodriguez-Sagrado MA. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection. Expert Rev Clin Pharmacol. 2018;11(6):561–570.
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
  • Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849.
  • Capetti AF, Sterrantino G, Cossu MV, et al. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther (Lond). 2017;22(3):257–262.
  • Capetti AF, Cossu MV, Orofino G, et al. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017;17:658.
  • Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Chronic Kidney Disease Epidemiology Collaboration. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–772.
  • Stanford University HIV Drug Resistance Database. Available: https://hivdb.stanford.edu/hivdb/by-mutations/report/. Accessed 23 July 2018.
  • CTCAE website. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 6 July 2018.
  • Stang A, Perry T, Fadul N. Darunavir and dolutegravir combination therapy in ART experienced HIV-infected patients: a preliminary report. OFID. 2017;4(S1):S431.
  • Wheeler J, Chan S, Harrigan PR, Becker M, Kasper K, Keynan Y. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada. Int J STD AIDS. 2018;29(5):520–522.
  • Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484–488.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.